Role of PLK1/NUMB/NOTCH in epithelial-mesenchymal transition in human melanoma

被引:0
作者
Gagan Chhabra
Chandra K. Singh
Mary A. Ndiaye
Shengqin Su
Carl A. Shirley
Nihal Ahmad
机构
[1] University of Wisconsin,Department of Dermatology
[2] William S. Middleton Memorial Veterans Hospital,undefined
来源
npj Precision Oncology | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Polo-like kinase 1 (PLK1), a serine/threonine kinase, is overexpressed in melanoma and its expression has been associated with poor disease prognosis. PLK1 has been shown to interact with NUMB, a NOTCH antagonist. However, the exact role of PLK1, NUMB, and NOTCH signaling in epithelial-mesenchymal transition (EMT) in melanoma progression is unclear. In this study, Affymetrix microarray analysis was performed to determine differentially expressed genes following shRNA-mediated knockdown of PLK1 in human melanoma cells that showed significant modulations in EMT and metastasis-related genes. Using multiple PLK1-modulated melanoma cell lines, we found that PLK1 is involved in the regulation of cell migration, invasion, and EMT via its kinase activity and NOTCH activation. In vitro kinase assay and mass spectrometry analysis demonstrated a previously unknown PLK1 phosphorylation site (Ser413) on NUMB. Overexpression of non-phosphorylatable (S413A) and phosphomimetic (S413D) mutants of NUMB in melanoma cells implicated the involvement of NUMB-S413 phosphorylation in cell migration and invasion, which was independent of NOTCH activation. To determine the clinical relevance of these findings, immunohistochemistry was performed using melanoma tissue microarray, which indicated a strong positive correlation between PLK1 and N-cadherin, a protein required for successful EMT. These findings were supported by TCGA analysis, where expression of high PLK1 with low NUMB or high NOTCH or N-cadherin showed a significant decrease in survival of melanoma patients. Overall, these results suggest a potential role of PLK1 in EMT, migration, and invasion of melanoma cells. Our findings support the therapeutic targeting of PLK1, NUMB, and NOTCH for melanoma management.
引用
收藏
相关论文
共 114 条
  • [1] Switzer B(2022)Managing Metastatic Melanoma in 2022: A Clinical Review JCO Oncol. Pr. 18 335-351
  • [2] Puzanov I(2013)The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res. 73 6848-6855
  • [3] Skitzki JJ(2016)Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics Mol. Cancer Ther. 15 1427-1435
  • [4] Hamad L(2017)Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma Cancer Lett. 394 13-21
  • [5] Ernstoff MS(2009)Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells J. Invest. Dermatol. 129 2843-2853
  • [6] Cholewa BD(2012)Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis Cancer Res. 72 3864-3872
  • [7] Liu X(2022)NUMB as a Therapeutic Target for Melanoma J. Invest. Dermatol. 142 1882-1892.e1885
  • [8] Ahmad N(2021)The role of NUMB/NUMB isoforms in cancer stem cells BMB Rep. 54 335-343
  • [9] Gutteridge RE(2022)Numb-PRRL promotes TGF-beta1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer Cell Death Dis. 13 1122-1131
  • [10] Ndiaye MA(2015)Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma Hepatology 62 315-686